Lantus (scientific name: insulin glargine) is a long-lasting insulin that individuals take once a day. Used for some diabetics taking insulin (but not all), daily insulin can be an important part of keeping your HbA1c in check. (Lantus is manufactured and sold by Sanofi Aventis.)
A different pharmaceutical company, Novo Nordisk, recently studied a 3-times-per-week shot of insulin – called “Insulin Degludec” – and compared it to Lantus. (Full story in Times of India here.) This clinical trial, conducted at 28 sites in the United States, Canada, India, and South Africa over 16 weeks, found that Insulin Degludec was just as effective at controlling HbA1c as Lantus. (Note: it wasn’t more effective – it was just as effective). Still, this might be an important option if approved for those people who don’t like to take daily shots. (Now that I think of it, that might be most people.) From the article:
Dr Anoop Misra, chairman of Fortis Hospital’s centre of excellence for diabetes, said, “This is quite a breakthrough. For the first time, we have a ultra-long acting insulin with stable action. This will lead to lesser injections (once in two days) for the patients with good blood sugar control.”
This was a phase 2 trial (I’m pretty sure it was this one) – with a little over 100 participants. In order for Novo Nordisk to get this approved, they’ll have to conduct a phase 3 trial over a longer time period with more participants. It doesn’t look like they’ve launched any such trial yet – but when they do, it will be listed on the Corengi website (as well as clinicaltrials.gov).
How Corengi works:
Create an account here.